<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38879571</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Effects of Pycnogenol&#xae; in people with post-COVID-19 condition (PYCNOVID): study protocol for a single-center, placebo controlled, quadruple-blind, randomized trial.</ArticleTitle><Pagination><StartPage>385</StartPage><MedlinePgn>385</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">385</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-024-08187-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A significant proportion of the global population has been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at some point since the onset of the pandemic. Although most individuals who develop coronavirus disease 2019 (COVID-19) recover without complications, about 6% have persistent symptoms, referred to as post-COVID-19 condition (PCC). Intervention studies investigating treatments that potentially alleviate PCC-related symptoms and thus aim to mitigate the global public health burden and healthcare costs linked to PCC are desperately needed. The PYCNOVID trial investigates the effects of Pycnogenol&#xae;, a French maritime pine bark extract with anti-inflammatory and antioxidative properties, versus placebo on patient-reported health status in people with PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a single-center, placebo-controlled, quadruple blind, randomized trial. We aim to randomly assign 150 individuals with PCC (1:1 ratio) to receive either 200&#xa0;mg Pycnogenol&#xae; or placebo daily for 12&#xa0;weeks. Randomization is stratified for duration of PCC symptoms (&#x2264;&#x2009;6&#xa0;months versus&#x2009;&gt;&#x2009;6&#xa0;months) and presence of symptomatic chronic disease(s). The primary endpoint is perceived health status at 12&#xa0;weeks (EuroQol-Visual Analogue Scale) adjusted for baseline values and stratification factors. Secondary endpoints include change in self-reported PCC symptoms, health-related quality of life, symptoms of depression and anxiety, cognitive function, functional exercise capacity, physical activity measured with accelerometry, and blood biomarkers for endothelial health, inflammation, coagulation, platelet function, and oxidative stress. Investigators, study participants, outcome assessors, and data analysts are blinded regarding the intervention assignment. Individuals with PCC were involved in the design of this study.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This is the first trial to investigate the effects of Pycnogenol&#xae; versus placebo on patient-reported health status in people with PCC. Should the trial proof clinical effectiveness, Pycnogenol&#xae; may serve as a therapeutic approach to mitigate symptoms associated with PCC.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The study is registered at ClinicalTrials.gov. :NCT05890534, June 6, 2023.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Radtke</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1723-1070</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. thomas.radtke@uzh.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>K&#xfc;nzi</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1862-2994</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0000-7871-8707</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasi</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8359-6177</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zens</LastName><ForeName>Kyra D</ForeName><Initials>KD</Initials><Identifier Source="ORCID">0000-0001-7979-076X</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Babette</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8293-9844</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anagnostopoulos</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6197-3023</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puhan</LastName><ForeName>Milo A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-4721-1879</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehr</LastName><ForeName>Jan S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-1113-9895</Identifier><AffiliationInfo><Affiliation>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05890534</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>50JZ5Z98QY</RegistryNumber><NameOfSubstance UI="C024070">pycnogenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="Y">Plant Extracts</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005419" MajorTopicYN="Y">Flavonoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Pycnogenol&#xae;</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>16</Day><Hour>12</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>16</Day><Hour>11</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>15</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38879571</ArticleId><ArticleId IdType="pmc">PMC11179231</ArticleId><ArticleId IdType="doi">10.1186/s13063-024-08187-6</ArticleId><ArticleId IdType="pii">10.1186/s13063-024-08187-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A, et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381:e074425. doi: 10.1136/bmj-2022-074425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074425</ArticleId><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al. Long COVID through a public health lens: an umbrella review. Public Health Rev. 2022;43:1604501. doi: 10.3389/phrs.2022.1604501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/phrs.2022.1604501</ArticleId><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. Plos One. 2021;16:e0254523. doi: 10.1371/journal.pone.0254523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957. doi: 10.1038/s41467-022-29521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2021;174:723&#x2013;725. doi: 10.7326/M20-5926.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5926</ArticleId><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet. 2022;400:452&#x2013;61. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittas V, Puhan MA. Post COVID-19 condition: definition, prevalence, therapy, pathogenesis, socio-economic implications, and relation to post-acute sequelae of other viral infections. 2023. Available from: https://www.bag.admin.ch/dam/bag/en/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/Literaturrecherchen/literaturrecherche-zustand-nach-covid-19-mai-2023.pdf.download.pdf/post-covid-19-condition.pdf (Accessed 27 Sept 2023)</Citation></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529. doi: 10.1136/bmj-2022-072529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T, Menges D, Kaufmann M, Amati R, Frei A, von Wyl V, et al. Post COVID-19 condition after wildtype, delta, and omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. Plos One. 2023;18:e0281429. doi: 10.1371/journal.pone.0281429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281429</ArticleId><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, et al. Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459. doi: 10.3389/fimmu.2023.1129459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, de MaertensNoordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473&#x2013;87. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41:3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long COVID&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzy NA, Abou Shaar B, Taha RM, Arabi TZ, Sabbah BN, Alkodaymi MS, et al. A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO international clinical trials platform. Clin Microbiol Infect. 2023;29:570&#x2013;577. doi: 10.1016/j.cmi.2023.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.01.007</ArticleId><ArticleId IdType="pmc">PMC9837206</ArticleId><ArticleId IdType="pubmed">36642173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Leber A, Jawad MY, Yu M, Lui LMW, Subramaniapillai M, et al. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect Dis (Lond) 2022;54:467&#x2013;477. doi: 10.1080/23744235.2022.2043560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2043560</ArticleId><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="pubmed">35282780</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcaro G, Cornelli U, Cesarone MR, Scipione C, Scipione V, Hu S, et al. Preventive effects of Pycnogenol&#xae; on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19) Minerva Med. 2022;113:300&#x2013;308. doi: 10.23736/S0026-4806.21.07650-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0026-4806.21.07650-3</ArticleId><ArticleId IdType="pubmed">34060731</ArticleId></ArticleIdList></Reference><Reference><Citation>Enseleit F, Sudano I, P&#xe9;riat D, Winnik S, Wolfrum M, Flammer AJ, et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J. 2012;33:1589&#x2013;1597. doi: 10.1093/eurheartj/ehr482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr482</ArticleId><ArticleId IdType="pubmed">22240497</ArticleId></ArticleIdList></Reference><Reference><Citation>Weichmann F, Rohdewald P. Projected supportive effects of Pycnogenol&#x24c7; in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection. Int J Antimicrob Agents. 2020;56:106191. doi: 10.1016/j.ijantimicag.2020.106191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106191</ArticleId><ArticleId IdType="pmc">PMC7546273</ArticleId><ArticleId IdType="pubmed">33045354</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res. 2007;30:775&#x2013;780. doi: 10.1291/hypres.30.775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1291/hypres.30.775</ArticleId><ArticleId IdType="pubmed">18037769</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlenhut K, H&#xf6;gger P. Facilitated cellular uptake and suppression of inducible nitric oxide synthase by a metabolite of maritime pine bark extract (Pycnogenol) Free Radic Biol Med. 2012;53:305&#x2013;313. doi: 10.1016/j.freeradbiomed.2012.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.04.013</ArticleId><ArticleId IdType="pubmed">22569413</ArticleId></ArticleIdList></Reference><Reference><Citation>Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol. 2009;9:1145&#x2013;1149. doi: 10.1016/j.intimp.2009.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2009.06.001</ArticleId><ArticleId IdType="pubmed">19508901</ArticleId></ArticleIdList></Reference><Reference><Citation>Post COVID-19 condition. Available from: https://www.who.int/teams/health-care-readiness/post-covid-19-condition. Cited 2023 Jun 26</Citation></Reference><Reference><Citation>Devlin NJ, Krabbe PFM. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ. 2013;14(Suppl 1):S1&#x2013;3. doi: 10.1007/s10198-013-0502-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-013-0502-3</ArticleId><ArticleId IdType="pmc">PMC3728454</ArticleId><ArticleId IdType="pubmed">23900659</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20:1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Borzeleca JF, Burdock GA, Thomas JA. Opinion of an expert panel on the Generally Recognized as Safe (GRAS) status of French maritime pine bark extract (Pycnogenol) as a flavoring agent&#xae;. Meyrin: Horphag Research; 2004.</Citation></Reference><Reference><Citation>Puhan MA, Frey M, Buchi S, Schunemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outc. 2008;6:46. doi: 10.1186/1477-7525-6-46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-6-46</ArticleId><ArticleId IdType="pmc">PMC2459149</ArticleId><ArticleId IdType="pubmed">18597689</ArticleId></ArticleIdList></Reference><Reference><Citation>Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George&#x2019;s respiratory questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol. 2003;56:1170&#x2013;6. doi: 10.1016/S0895-4356(03)00115-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(03)00115-X</ArticleId><ArticleId IdType="pubmed">14680667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Goldstein R, Mador MJ, McKim D, Stahl E, Griffith LE, et al. Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease. Qual Life Res. 2006;15:1&#x2013;14. doi: 10.1007/s11136-005-0126-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-005-0126-x</ArticleId><ArticleId IdType="pubmed">16411026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63&#x2013;74. doi: 10.1016/S0885-3924(96)00274-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0885-3924(96)00274-6</ArticleId><ArticleId IdType="pubmed">9095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Montan I, L&#xf6;we B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21:1313&#x2013;1321. doi: 10.1016/j.jval.2018.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2018.03.013</ArticleId><ArticleId IdType="pubmed">30442279</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin &#xc5;, Taft C, Lundgren-Nilsson &#xc5;, Dencker A. Minimal important differences for fatigue patient reported outcome measures-a systematic review. BMC Med Res Methodol. 2016;16:62. doi: 10.1186/s12874-016-0167-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0167-6</ArticleId><ArticleId IdType="pmc">PMC4937582</ArticleId><ArticleId IdType="pubmed">27387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlis C, Singh S, Gardiner N, Houchen-Wolloff L, Chaplin E, Daynes E. Proposed MID in FACIT and VAS scores for individuals attending COVID-19 rehabilitation. European Respiratory Journal. 2021;58. Available from: https://erj.ersjournals.com/content/58/suppl_65/OA162. Cited 2022 Jul 18</Citation></Reference><Reference><Citation>Puhan MA, Behnke M, Laschke M, Lichtenschopf A, Brandli O, Guyatt GH, et al. Self-administration and standardisation of the chronic respiratory questionnaire: a randomised trial in three German-speaking countries. Respir Med. 2004;98:342&#x2013;350. doi: 10.1016/j.rmed.2003.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2003.10.013</ArticleId><ArticleId IdType="pubmed">15072175</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773&#x2013;778. doi: 10.1136/thx.42.10.773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.42.10.773</ArticleId><ArticleId IdType="pmc">PMC460950</ArticleId><ArticleId IdType="pubmed">3321537</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) Thorax. 2001;56:954&#x2013;959. doi: 10.1136/thorax.56.12.954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thorax.56.12.954</ArticleId><ArticleId IdType="pmc">PMC1745990</ArticleId><ArticleId IdType="pubmed">11713359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzola M, Hanania NA, MacNee W, R&#xfc;dell K, Hackford C, Tamimi N. A review of the most common patient-reported outcomes in COPD&#x2013;revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015;10:725&#x2013;738. doi: 10.2147/COPD.S77368.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S77368</ArticleId><ArticleId IdType="pmc">PMC4396518</ArticleId><ArticleId IdType="pubmed">25897216</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivelli L, Palmer K, Calandri I, Guekht A, Beghi E, Carroll W, et al. Changes in cognitive functioning after COVID-19: a systematic review and meta-analysis. Alzheimers Dement. 2022;18:1047&#x2013;1066. doi: 10.1002/alz.12644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12644</ArticleId><ArticleId IdType="pmc">PMC9073922</ArticleId><ArticleId IdType="pubmed">35297561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263&#x2013;1276. doi: 10.1093/brain/awab009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto OH, Rumbea DA, Recalde BY, Mera RM. Cognitive sequelae of long COVID may not be permanent: a prospective study. Eur J Neurol. 2022;29:1218&#x2013;1221. doi: 10.1111/ene.15215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15215</ArticleId><ArticleId IdType="pubmed">34918425</ArticleId></ArticleIdList></Reference><Reference><Citation>Daroische R, Hemminghyth MS, Eilertsen TH, Breitve MH, Chwiszczuk LJ. Cognitive impairment after COVID-19-a review on objective test data. Front Neurol. 2021;12:699582. doi: 10.3389/fneur.2021.699582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.699582</ArticleId><ArticleId IdType="pmc">PMC8357992</ArticleId><ArticleId IdType="pubmed">34393978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695&#x2013;699. doi: 10.1111/j.1532-5415.2005.53221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52:69&#x2013;77. doi: 10.1016/S0022-3999(01)00296-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(01)00296-3</ArticleId><ArticleId IdType="pubmed">11832252</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann C. International experiences with the Hospital Anxiety and Depression Scale&#x2013;a review of validation data and clinical results. J Psychosom Res. 1997;42:17&#x2013;41. doi: 10.1016/S0022-3999(96)00216-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(96)00216-4</ArticleId><ArticleId IdType="pubmed">9055211</ArticleId></ArticleIdList></Reference><Reference><Citation>Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outc. 2003;1:29. doi: 10.1186/1477-7525-1-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-1-29</ArticleId><ArticleId IdType="pmc">PMC183845</ArticleId><ArticleId IdType="pubmed">12914662</ArticleId></ArticleIdList></Reference><Reference><Citation>Smid DE, Franssen FME, Houben-Wilke S, Vanfleteren LEGW, Janssen DJA, Wouters EFM, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. J Am Med Dir Assoc. 2017;18:53&#x2013;58. doi: 10.1016/j.jamda.2016.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2016.08.002</ArticleId><ArticleId IdType="pubmed">27624705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease. J Cardiopulm Rehabil Prev. 2019;39:E6&#x2013;11. doi: 10.1097/HCR.0000000000000379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCR.0000000000000379</ArticleId><ArticleId IdType="pubmed">30489438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Levis B, Sun Y, He C, Krishnan A, Neupane D, et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021;373:n972. doi: 10.1136/bmj.n972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n972</ArticleId><ArticleId IdType="pmc">PMC8107836</ArticleId><ArticleId IdType="pubmed">33972268</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya T, Chambellan A, de Bisschop C. Sit-to-stand tests for COPD: a literature review. Respir Med. 2017;128:70&#x2013;77. doi: 10.1016/j.rmed.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2017.05.003</ArticleId><ArticleId IdType="pubmed">28610673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanini A, Crisafulli E, D&#x2019;Andria M, Gregorini C, Cherubino F, Zampogna E, et al. Minimum clinically important difference in 30-s sit-to-stand test after pulmonary rehabilitation in subjects with COPD. Respir Care. 2019;64:1261&#x2013;1269. doi: 10.4187/respcare.06694.</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.06694</ArticleId><ArticleId IdType="pubmed">31270178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozcan Kahraman B, Ozsoy I, Akdeniz B, Ozpelit E, Sevinc C, Acar S, et al. Test-retest reliability and validity of the timed up and go test and 30-second sit to stand test in patients with pulmonary hypertension. Int J Cardiol. 2020;304:159&#x2013;163. doi: 10.1016/j.ijcard.2020.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2020.01.028</ArticleId><ArticleId IdType="pubmed">31980271</ArticleId></ArticleIdList></Reference><Reference><Citation>Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nystr&#xf6;m C, Mora-Gonzalez J, L&#xf6;f M, et al. Accelerometer data collection and processing criteria to assess physical activity and other outcomes: a systematic review and practical considerations. Sports Med. 2017;47:1821&#x2013;1845. doi: 10.1007/s40279-017-0716-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40279-017-0716-0</ArticleId><ArticleId IdType="pmc">PMC6231536</ArticleId><ArticleId IdType="pubmed">28303543</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi L, Ward SC, Schnelle JF, Buchowski MS. Assessment of wear/nonwear time classification algorithms for triaxial accelerometer. Med Sci Sports Exerc. 2012;44:2009&#x2013;2016. doi: 10.1249/MSS.0b013e318258cb36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/MSS.0b013e318258cb36</ArticleId><ArticleId IdType="pmc">PMC3443532</ArticleId><ArticleId IdType="pubmed">22525772</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Lozano A, Sant&#xed;n-Medeiros F, Cardon G, Torres-Luque G, Bail&#xf3;n R, Bergmeir C, et al. Actigraph GT3X: validation and determination of physical activity intensity cut points. Int J Sports Med. 2013;34:975&#x2013;982. doi: 10.1055/s-0033-1337945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0033-1337945</ArticleId><ArticleId IdType="pubmed">23700330</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Pine AB, Meizlish ML, Chang C-H, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575&#x2013;e582. doi: 10.1016/S2352-3026(20)30216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Late-onset hematological complications post COVID-19: an emerging medical problem for the hematologist. Am J Hematol. 2022;97:119&#x2013;128. doi: 10.1002/ajh.26384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26384</ArticleId><ArticleId IdType="pmc">PMC8646944</ArticleId><ArticleId IdType="pubmed">34687462</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Wong SW, Sum CLL, Lim GH, Leung BP, Tan CW, et al. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients. Am J Hematol. 2022;97:915&#x2013;923. doi: 10.1002/ajh.26575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26575</ArticleId><ArticleId IdType="pmc">PMC9073976</ArticleId><ArticleId IdType="pubmed">35477923</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleeson EM, O&#x2019;Donnell JS, Preston RJS. The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cell Mol Life Sci. 2012;69:717&#x2013;726. doi: 10.1007/s00018-011-0825-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-011-0825-0</ArticleId><ArticleId IdType="pmc">PMC11115159</ArticleId><ArticleId IdType="pubmed">21968919</ArticleId></ArticleIdList></Reference><Reference><Citation>Jud P, Gressenberger P, Muster V, Avian A, Meinitzer A, Strohmaier H, et al. Evaluation of endothelial dysfunction and inflammatory vasculopathy after SARS-CoV-2 infection&#x2014;a cross-sectional study. Front Cardiovasc Med. 2021;8:750887. doi: 10.3389/fcvm.2021.750887.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.750887</ArticleId><ArticleId IdType="pmc">PMC8549830</ArticleId><ArticleId IdType="pubmed">34722682</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzeh-Cognasse H, Mansour A, Reizine F, Mismetti P, Gouin-Thibault I, Cognasse F. Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection. Virol J. 2021;18:211. doi: 10.1186/s12985-021-01680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-021-01680-3</ArticleId><ArticleId IdType="pmc">PMC8554745</ArticleId><ArticleId IdType="pubmed">34715884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88:15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res. 2020;127:945&#x2013;947. doi: 10.1161/CIRCRESAHA.120.317803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317803</ArticleId><ArticleId IdType="pmc">PMC7478197</ArticleId><ArticleId IdType="pubmed">32757722</ArticleId></ArticleIdList></Reference><Reference><Citation>Martyanov AA, Boldova AE, Stepanyan MG, An OI, Gur&#x2019;ev AS, Kassina DV, et al. Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: effects of disease severity, anticoagulation therapy and inflammatory status. Thromb Res. 2022;211:27&#x2013;37. doi: 10.1016/j.thromres.2022.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.01.013</ArticleId><ArticleId IdType="pmc">PMC8761024</ArticleId><ArticleId IdType="pubmed">35066204</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200:e70&#x2013;88. doi: 10.1164/rccm.201908-1590ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201908-1590ST</ArticleId><ArticleId IdType="pmc">PMC6794117</ArticleId><ArticleId IdType="pubmed">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3&#x2013;95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324&#x2013;1343. doi: 10.1183/09031936.00080312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00080312</ArticleId><ArticleId IdType="pmc">PMC3786581</ArticleId><ArticleId IdType="pubmed">22743675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler S, Raineri A, Nittas V, Rangelov N, Vollrath F, Britt C, et al. Long COVID citizen scientists: developing a needs-based research agenda by persons affected by long COVID. Patient. 2022;15:565&#x2013;576. doi: 10.1007/s40271-022-00579-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40271-022-00579-7</ArticleId><ArticleId IdType="pmc">PMC9046008</ArticleId><ArticleId IdType="pubmed">35478078</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow G. blockrand: randomization for block random clinical trials. R package v. 2022. Available from: https://CRAN.R-project.org/package=blockrand</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)&#x2013;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2013;381. doi: 10.1016/j.jbi.2008.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, De Groote W, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715&#x2013;724. doi: 10.1016/S2213-2600(22)00169-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hare AM, Vig EK, Iwashyna TJ, Fox A, Taylor JS, Viglianti EM, et al. Complexity and challenges of the clinical diagnosis and management of long COVID. JAMA Netw Open. 2022;5:e2240332. doi: 10.1001/jamanetworkopen.2022.40332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.40332</ArticleId><ArticleId IdType="pmc">PMC9634500</ArticleId><ArticleId IdType="pubmed">36326761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>